No Evidence of Linkage for Chromosome 1q42.2-43 in Prostate Cancer  by Whittemore, Alice S. et al.
Am. J. Hum. Genet. 65:254–256, 1999
254
Letters to the Editor
Am. J. Hum. Genet. 65:254, 1999
No Evidence of Linkage for Chromosome 1q42.2-43
in Prostate Cancer
To the Editor:
On the basis of a genomewide search involving 47
French and German families with multiple cases of pros-
tate cancer, Berthon et al. (1998) reported linkage to
chromosomal region 1q42.2-43 (multipoint nonpara-
metric Z score of 3.1, at marker D1S2785).P  .001
This finding is interesting because, although D1S2785
is considerably distal to the region 1q24-25—identified
by Smith et al. (1996) as containing the putative hered-
itary prostate cancer locus HPC1—it is only 14 cM away
from the marker D1S235, which also produced an ele-
vated Z score in the scan by Smith et al. In an attempt
to confirm the finding by Berthon et al., we have eval-
uated linkage to three markers in the 1q42.2-43 region
in 97 unrelated families containing three or more med-
ically verified diagnoses of prostate cancer in first- or
second-degree relatives. Eighty-two of these families ful-
filled one or more of the proposed criteria for families
whose prostate cancer is likely to be hereditary (i.e., three
or more affected individuals within one nuclear family,
affected individuals in three successive generations, and/
or two or more individuals affected at age !55 years).
Seven families were African American, four were Japa-
nese American, and three were Chinese American. The
families were identified from several sources, described
by Hsieh et al. (1997). The mean number, per family, of
affected and genotyped individuals was 2.6 (range 2–5),
and the mean age at diagnosis of all affected individuals
was 66.9 years (67.0 years in white families, 64.1 years
in African American families, 69.2 years in Asian Amer-
ican families). The overall number of genotyped affected
individuals and the overall mean age at diagnosis are
similar to those found for the families reported by Ber-
thon et al. (1998). A total of 382 samples were geno-
typed for the three markers. Genotyping was performed
by the NHLBI (National Heart, Lung, and Blood Insti-
tute) Mammalian Genotyping Service at the Marshfield
Medical Foundation (Yuan et al. 1997), by use of an
ABI 377 sequencer to read fluorescently labeled primers
for PCR products. We retyped individuals with ambig-
uous or missing genotypes and also retyped one or more
relatives of each such individual to insure interlabora-
tory comparability. All samples were typed without
knowledge of disease status.
Parametric LOD scores, nonparametric Z scores, and
one-tailed P values were obtained with the software
GENEHUNTER (Kruglyak et al. 1996). For the para-
metric analyses, we assumed an autosomal dominant
mode of inheritance of a disease-susceptibility allelewith
frequency .003 and with penetrances as estimated in the
segregation analysis by Carter et al. (1992). For the mul-
tipoint analyses, the three markers were assumed to be
in the order shown in table 1. We estimated allele fre-
quencies for the three markers in family founders, using
the software FASTLINK (Cottingham et al. 1993; Schaf-
fer et al. 1994).
Table 1 shows the three markers analyzed and their
estimated positions in relation to D1S2785, the marker
most strongly linked in the data of Berthon et al. (1998).
Table 1 also shows multipoint LOD scores and non-
parametric Z scores among the 48 families with mean
age at diagnoses !67 years, among the 49 remaining
families, and among all families. The negative values of
the LOD scores and Z scores and the nonsignificant P
values provide no support for linkage. The threemarkers
each had negative two-point Z scores, and either neg-
ative or very small positive heterogeneity LOD scores.
Berthon et al. found stronger evidence for linkage when
analysis was restricted to the nine families in their data
for which the age at diagnosis of all affected members
in the last generation was !60 years. In contrast, we
found negative scores similar to those in table 1 when
we analyzed the 14 families in the present data who
satisfied this criterion.
Thus, the present data do not support the possibility
of a prostate cancer–susceptibility gene in the 1q42.2-
43 region. Although the reasons for this lack of confir-
mation are unclear, several possible explanations come
to mind. First, the spikes in this region seen by both
Smith et al. and Berthon et al. could be due to chance,
since the evidence supporting linkage is somewhat weak.
The P value of .001 for the Z score of 3.1 for marker
D1S2785, reported by Berthon et al., does not reflect
the multiple testing involved in their genome scan. As
Whittemore et al.: Letters to the Editor 255
Table 1
Multipoint Z Values and NPL Z Values in 97 Families with Prostate Cancer, for Three Markers in Chromosomal
Region 1q42.2–43
MARKER
DISTANCEa
(cM)
MEAN AGE AT
ONSET !67 YEARS
(48 FAMILIES)
MEAN AGE AT
ONSET 167 YEARS
(49 FAMILIES) ALL 97 FAMILIES
Multipoint Z NPLZ (P) Multipoint Z NPL Z (P) Multipoint Z NPL Z (P)
D1S235 10.6 11.46 1.05 (.85) 8.82 .40 (.31) 10.18 .08 (.46)
D1S2785 0 ) ) ) ) ) )
D1S547 2.3 16.42 1.52 (.94) 12.83 1.01 (.84) 14.69 1.04 (.85)
D1S1609 9.3 18.98 1.92 (.98) 10.78 .36 (.63) 14.69 .97 (.83)
a From D1S2785, the marker most strongly linked in the data of Berthon et al. (1998).
noted by Lander and Kruglyak (1995), a nominal P
value of .001, such as that reported by Berthon et al.,
can be expected to occur by chance once in every genome
scan. To keep the chance of encountering a false positive
5%, one must impose a threshold of nonparametric Z
score 14.1, LOD score 13.6, which corresponds to a
significance level of .5P  2# 10
A second possible explanation for the lack of confir-
mation is differences in ancestry and ethnicity in the two
sets of families. Although most of the families in the
present analysis were white and of European ancestry,
their genetic heritage differs from that of the French and
German families analyzed by Berthon et al.
Prostate cancer may be diagnosed at a more advanced
stage in France and Germany than in the United States,
because of international differences in the prevalence of
screening with prostate-specific antigen (PSA). However,
such differences are unlikely to explain the discrepant
results, because most of the prostate cancers in the pre-
sent U.S. series were diagnosed before PSA screening
became prevalent. Moreover, there is no evidence that
PSA screening is less likely to detect inherited cancer than
sporadic cancer.
The lack of confirmation for this locus mirrors the
difficulties in confirmation of the HPC1 locus. Some data
have shown only weak confirmation (Hsieh et al. 1997;
Cooney et al. 1997), whereas other data do not support
linkage (McIndoe et al. 1997; Eeles 1998). This ambi-
guity may reflect considerable heterogeneity in heredi-
tary prostate cancer, with any one locus accounting for
only a small fraction of such disease. It also may reflect
an inability to identify sporadics and to model them
correctly.
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